VYNE - VYNE Therapeutics' Amzeeq and Zilxi approved in Chinese economic pilot zone

VYNE Therapeutics (NASDAQ:VYNE) perks up 4% premarket after announcing that its products AMZEEQ (minocycline) topical foam, 4%, and ZILXI (minocycline) topical foam, 1.5%, have been approved for commercial sale in a pilot program in Hainan Boao Lecheng, China. The drug will be sold in the region by Cutia Therapeutics, which licensed the exclusive rights to market AMZEEQ and ZILXI in Greater China. VYNE entered into a licensing agreement in 2020 with an affiliate of Cutia Therapeutics, a privately-owned company in China with a focus in dermatology. In addition to supplying AMZEEQ and ZILXI in the Boao Lecheng International Medical Tourism Pilot Zone, Cutia intends to seek full regulatory approval of both products in China and has recently begun recruiting patients in a Phase 3 trial for AMZEEQ.

For further details see:

VYNE Therapeutics' Amzeeq and Zilxi approved in Chinese economic pilot zone